This enabled the DCIS biosignature to account for the interdependencies and activation of the oncogenic pathways commonly dysregulated in DCIS such as estrogen response pathway, HER2 pathway, cell cycle, survival and stress response leading to increased proliferation and cell survival. Here, ERBB2 is linked to ductal breast carcinoma in situ.